102例造血系统肿瘤患者血清可溶性肿瘤坏死因子受体-I测定  

DETECTION AND EVALUATION OF SERUM SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR IN 102 PATIENTS WITH HEMATOLOGICAL MALIGNANCY

作　　者：蔡竞蕙[1] 周柱[1] 王裕发[1] 

机构地区：[1]上海市第一人民医院,上海200080

出　　处：《白血病》2000年第1期28-30,共3页

摘　　要：目的 :评估血清可溶性肿瘤坏死因子受体 - I( s TNFR- I)在造血系统肿瘤中的作用和临床意义。方法 :用夹心免疫酶联法测定 10 2例造血系统肿病患者和 61例健康人血清可溶性肿瘤坏死因子受体变化。结果 :造血系统肿瘤患者血清 s TNFR- I平均水平明显高于健康对照组 ( P<0 .0 1) ,其中急性白血病、多发性骨髓瘤、非霍奇金淋巴瘤血清 s TNFR- I较慢性粒细胞白血病、骨髓增生异常综合征升高更明显 ,对化疗有反应者低于化疗前 ,无反应者没有变化 ,复发后血清 s TNFR- I明显高于健康对照组 ,差别均有显著性 ( P<0 .0 1)。结论 :造血系统肿瘤患者血清 s TNFR- I水平与病种、病程和对化疗的反应相关 ,对造血系统肿瘤的检测、随访和预后的评估有辅助诊断意义。Objective:In order to elucidate clinical significance of serum level of soluble tumor necrosis factor receptor(sTNFR) in the patients with hematological malignancy.Methods: The serum sTNFR 1 level were measured with sandwich enzyme immunoassay in 102 cases of hematological malignancy and 61 health individuals.Results: The mean concentration of serum sTNFR 1 was significantly increased in the patients with hematological malignancy compared with that in normal control( P <0.01). The serum sTNFR 1 levels were much higher in the patients with acute leukemia,multiple myeloma and non Hodgikin lymphoma than those in the patients with chronic myeloid leukemia and myelodysplastic syndrome. The serum level of sTNFR 1 in the patients with response to chemotherapy decreased significantly compared with that before chemotherapy. However,no significant change in serum sTNFR 1 was observed in the patients without any responses before and after chemotherapy. When relapse occurred,serum sTNFR 1 would return to higher level.Conclusion: The serum sTNFR 1 level in patients with hematological malignancy may correlate well with the kinds and the courses of diseases and the reponses to chemotherapy. Therefore,the measurement of serum sTNFR 1 may helpful in the detection of hematological malignancy,the evaluation of prognosis and the follow up studies.

关 键 词：造血系统肿瘤 药物疗法 STNFR-I 

分 类 号：R733[医药卫生—肿瘤]